◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksU › UTHR

United Therapeutics Corporation (UTHR) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-09-19

United Therapeutics Corporation (UTHR) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Silver Spring, United States with about 1,400 employees. Its market capitalization is roughly $21 billion. In the fiscal year ended 2025-12-31, UTHR reported $3.2B in revenue and $1.3B in net income.

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Interactive charts & full statements → Open the UTHR valuation workbench →

UTHR Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Revenue$3.2B$3.2B$2.9B$2.3B$1.9B$1.7B$1.5B$1.4B$1.6B$1.7B$1.6B$1.5B$1.3B$1.1B$916M$743M$604M$370M$281M$211M$160M
Gross Profit$2.7B$2.8B$2.6B$2.1B$1.8B$1.6B$1.4B$1.3B$1.4B$1.6B$1.5B$1.4B$1.2B$986M$797M$654M$530M$325M$251M$189M$143M
Gross Margin %86.2%87.9%89.2%88.9%92.4%92.7%92.7%91.9%87.8%93.9%95.5%95.3%90.2%88.3%87.0%88.0%87.8%87.8%89.3%89.5%89.3%
Operating Income (EBIT)$1.4B$1.5B$1.4B$1.2B$980M$556M$594M($188M)$805M$815M$1.1B$699M$539M$292M$422M$318M$164M$26M($82M)$6M$29M
Operating Margin %44.5%47.7%47.9%50.9%50.6%33.0%40.0%-13.0%49.5%47.2%66.4%47.7%41.8%26.2%46.0%42.8%27.2%7.0%-29.1%3.0%18.2%
Net Income$1.3B$1.3B$1.2B$985M$727M$476M$515M($104M)$589M$418M$714M$652M$340M$175M$304M$218M$106M$19M($43M)$20M$74M
Net Margin %41.5%41.9%41.5%42.3%37.6%28.2%34.7%-7.2%36.2%24.2%44.6%44.5%26.4%15.6%33.2%29.3%17.5%5.3%-15.2%9.4%46.3%
EBITDA$1.8B$1.7B$1.4B$1.0B$737M$646M($75M)$838M$1.1B$1.1B$1.1B$575M$324M$484M$341M$185M$43M($68M)$22M$29M
Earnings Per Share (EPS)$27.86$27.86$24.64$19.81$15.00$10.06$11.54$-2.39$13.39$9.31$15.25$12.72$6.28$3.28$5.71$3.67$1.78$0.35$-0.93$0.44$1.53
Shares Outstanding (M)48M48M50M48M47M45M44M44M45M47M51M54M53M53M59M60M56M46M45M48M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

UTHR Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue$783M$782M$790M$800M$799M$794M$736M$749M$715M
Gross Profit$684M$648M$687M$699M$711M$702M$660M$666M$637M
Gross Margin %87.4%82.9%86.9%87.4%89.0%88.4%89.7%88.9%89.1%
Operating Income (EBIT)$331M$326M$358M$389M$364M$383M$358M$343M$320M
Operating Margin %42.3%41.7%45.2%48.7%45.6%48.2%48.6%45.8%44.8%
Net Income$333M$275M$364M$339M$310M$322M$301M$309M$278M
Net Margin %42.5%35.2%46.1%42.4%38.8%40.6%40.9%41.3%38.9%
EBITDA$344M$470M$463M$437M$437M$424M$418M$386M
Earnings Per Share (EPS)$7.27$5.82$7.61$7.16$6.41$6.63$6.19$6.39$5.85
Shares Outstanding (M)47M48M47M48M49M49M48M48M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

UTHR Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Cash from Operations (CFO)$1.7B$1.6B$1.3B$978M$802M$598M$756M($207M)$778M$474M$644M$383M$355M$425M$324M$250M$212M$100M($49M)$49M$49M
Capital Expenditures (CapEx)$592M$520M$246M$230M$139M$121M$59M$84M$184M$86M$43M$50M$47M$32M$112M$36M$19M$95M$124M$39M$16M
Free Cash Flow (FCF)$1.1B$1.0B$1.1B$748M$664M$477M$696M($290M)$594M$388M$600M$333M$308M$393M$212M$214M$193M$4M($174M)$10M$34M
FCF Margin %34.6%32.7%37.5%32.1%34.3%28.3%46.9%-20.0%36.5%22.5%37.5%22.7%23.9%35.2%23.1%28.8%31.9%1.2%-61.7%4.9%21.1%
Dividends Paid$98M$94M$38M$14M$0M$8M$39M$190M$27M$0M$0M$0M$30M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

UTHR Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Cash from Operations (CFO)$314M$463M$346M$562M$192M$461M$341M$377M$232M
Capital Expenditures (CapEx)$108M$101M$173M$210M$62M$75M$87M$76M$45M
Free Cash Flow (FCF)$206M$362M$173M$352M$130M$386M$254M$301M$187M
FCF Margin %26.3%46.4%21.9%44.0%16.2%48.6%34.6%40.2%26.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

UTHR Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Assets$7.2B$7.9B$7.4B$7.2B$6.0B$5.2B$4.6B$3.9B$3.4B$2.9B$2.3B$2.2B$1.9B$2.1B$1.6B$1.5B$1.4B$1.1B$871M$587M$479M
Cash & Cash Equivalents$1.8B$1.6B$1.7B$1.2B$961M$895M$739M$738M$669M$705M$1.0B$832M$398M$279M$154M$163M$252M$100M$129M$139M$91M
Total Liabilities$820M$784M$920M$1.2B$1.2B$1.2B$1.2B$1.1B$612M$778M$463M$585M$619M$783M$532M$570M$548M$399M$364M$291M$274M
Total Debt (Short + Long-Term)$7M$300M$700M$800M$800M$800M$850M$250M$500M$0M$5M$126M$286M$275M$266M$305M$251M$279M$250M$250M
Total Shareholders' Equity$6.4B$7.1B$6.4B$6.0B$4.8B$4.0B$3.4B$2.8B$2.8B$2.1B$1.9B$1.6B$1.3B$1.3B$1.1B$948M$884M$653M$508M$296M$205M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive UTHR viewer.

UTHR Metric Deep Dives

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← UTGAll “U” companiesUTHY →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.